Arrivo and its subsidiaries, Sirtsei Pharmaceuticals and Panafina, Inc, are focused on conducting clinical trials to bring these important medications to patients as quickly, and as safely, as possible.  We are a small team and believe prioritizing our resources on these clinical development programs is the best strategy for helping patients in the long-term.  Therefore, currently, we do not offer expanded access programs for any of our investigational products.

In the interim, the best way to access our investigational products is through participating in clinical trials.  If you would like to learn more about our clinical trials, you can find additional information on the clinicaltrials.gov website at the following links:

https://www.clinicaltrials.gov/search?term=sirtsei&viewType=Table

https://www.clinicaltrials.gov/search?term=panafina&viewType=Table

Arrivo regularly reviews its policies to ensure we are in compliance with all rules and regulations, and we reserve the right to update our expanded access policy as circumstances change.

If you have additional questions regarding our expanded access policy, please email us at expandedaccess@arrivobio.com.